BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 865 filers reported holding BAXTER INTL INC in Q4 2015. The put-call ratio across all filers is 0.33 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $16,000 | -99.0% | 200 | -99.2% | 0.00% | -99.7% |
| Q2 2017 | $1,612,000 | +15.2% | 26,624 | 0.0% | 0.61% | +1.8% |
| Q1 2017 | $1,399,000 | +18.6% | 26,624 | 0.0% | 0.60% | -3.4% |
| Q4 2016 | $1,180,000 | -7.0% | 26,624 | -0.2% | 0.62% | -15.5% |
| Q3 2016 | $1,269,000 | +5.2% | 26,675 | 0.0% | 0.74% | -3.3% |
| Q2 2016 | $1,206,000 | +10.3% | 26,675 | +0.2% | 0.76% | +0.8% |
| Q1 2016 | $1,093,000 | +7.7% | 26,610 | 0.0% | 0.76% | +9.9% |
| Q4 2015 | $1,015,000 | – | 26,610 | – | 0.69% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GENERATION INVESTMENT MANAGEMENT LLP | 21,171,371 | $1,817,350,000 | 7.47% |
| Soditic Asset Management LLP | 147,620 | $12,672,000 | 6.53% |
| NUANCE INVESTMENTS, LLC | 4,084,218 | $350,589,000 | 6.17% |
| PRAGMA GESTAO DE PATRIMONIO LTD | 145,000 | $12,447 | 5.96% |
| Veritas Asset Management LLP | 12,222,261 | $1,049,159,000 | 5.89% |
| Pavadi Capital LLC | 72,782 | $6,248,000 | 4.74% |
| Sonen Capital LLC | 48,907 | $4,198,000 | 4.06% |
| Glenview Capital Management | 2,182,422 | $187,339,000 | 3.99% |
| Dash Acquisitions Inc. | 103,963 | $8,924,000 | 3.87% |
| Avidity Partners Management LP | 1,765,000 | $151,508,000 | 3.21% |